Onconetix (NASDAQ:ONCO) Releases Quarterly Earnings Results, Beats Estimates By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($76.01) earnings per share for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%.

Onconetix Price Performance

ONCO stock traded down $0.30 during trading hours on Monday, reaching $2.91. The stock had a trading volume of 62,174 shares, compared to its average volume of 167,959. The stock has a market capitalization of $1.72 million, a PE ratio of 0.00 and a beta of 2.62. The stock has a 50-day simple moving average of $6.24 and a 200 day simple moving average of $110.32. Onconetix has a fifty-two week low of $2.76 and a fifty-two week high of $1,610.00.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ONCO shares. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Read Our Latest Report on Onconetix

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Read More

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.